Clinical commentary: The bromocriptine (Parlodel) controversy and recommendations for lactation suppression

American Journal of Perinatology

Volumn 13, Issue 2, 1996, Pages 69-71

  Rayburn, William F ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

breast engorgement; breast feeding; Lactation suppression

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; DOPAMINE RECEPTOR; PROLACTIN;

ADULT; ARTICLE; BREAST FEEDING; BREAST MILK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; LACTATION INHIBITION; MASTALGIA; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; THROMBOEMBOLISM;

EID: 0030023762     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994294     Document Type: Article

References (18)

1. The puerperium. In Cunningham FG, MacDonald PC, Gant N, et al (eds). Williams Obstetrics (19th ed). Norwalk, CT: Appleton and Lange, 1993;462-4
2. Morris JA, Creasy RK, Hohe PT. Inhibition of puerperal lactation: double-blind comparison of chlorotrianisene, testosterone enanthate with estradiol valerate, and placebo. Obstet Gynecol 1970;36:107-12
3. Martin KE, Wolst MD. A comparative controlled study of hormones in the prevention of postpartum breast engorgement and lactation. Am J Obstet Gynecol 1960;80:128-32
4. Womack WS, Smith SW, Allen GM. A comparison of hormone therapies for suppression of lactation. South Med J 1962;55:816-21
5. Iliya FA, Safon L, O'Leary JA, Testosterone enanthate (180 mg) and estradiol valerate (8 mg) for suppression of lactation: a double-blind evaluation. Obstet Gynecol 1966; 27:643-7
6. Daniel DG, Campbell H, Turnbull AC. Puerperal thromboembolism and suppression of lactation. Lancet 1967;2: 287-9
7. Turnbull AC. Puerperal thromboembolism and the suppression of lactation. J Obstet Gynaecol Br Commonw 1968;75:1322-5
8. Nilsen PA, Meling A-B, Abildgaard U. Study of the suppression of lactation and the influence on blood clotting with bromocriptine (CB-154) (Parlodel): a double-blind comparison with diethylstilbestrol. Acta Obstet Gynecol Scand 1976;55:39-44
9. Seppala M, Ylinen O, Sternthal V, et al. Suppression of established puerperal lactation with 2-Br-alpha-ergocryptine methane sulphonate (CB 154). Int J Gynaecol Obstet 1975; 13:1-5
10. Thorbert G, Akerlund M. Inhibition of lactation by cyclofenil and bromocriptine. Br J Obstet Gynecol 1983;90: 739-42
11. Giorda G, de Vincenrilis S, Moffa T, et al. Cabergoline versus bromocriptine in suppression of lactation after caesarean delivery. Gynecol Obstet Invest 1991;31:93-6
12. Sandoz Pharmaceuticals. Drug information brochure: Parlodel (bromocriptine mesylate). Sandoz Pharmaceuticals, East Hanover, NJ, 1987
13. Parlodel. Physicians Desk Reference. Oradel, NJ: Medical Economics Co., 1994:2067-8
14. Postpartum hypertension, seizures, strokes reported with bromocriptine. Division of Drug Experience (HFN-730). FDA Bulletin, May 1990
15. A Sandoz drug generates a wave of lawsuits. Wall Street J August 16, 1994:B1,B6
16. Rayburn WF. A physician's prerogative to prescribe drugs for off-label uses during pregnancy. Obstet Gynecol 1993;81: 1052-5
17. American Academy of Pediatrics and American College of Obstetricians and Gynecologists Guidelines for Perinatal Care, 3rd ed. Washington, DC: American College of Obstetricians and Gynecologists, 1992:183
18. Lucas A, Morley R, Cole T, et al. Breast milk and subsequent intelligence quotient in children born preterm. Lancet 1992;339:261-5